Phigenix is developing state-of-the-art technology in cancer Personalized Medicine from a portfolio of over 100 patents and pending patents.
PHIGENIX is a leader in developing diagnostics and targeted therapies which may assist physicians in determining treatment regime. With these diagnostic tests, prostate and breast cancer patients likely to benefit maximally from a particular therapy can be identified, and other patients for whom alternative therapies (e.g. hormonal manipulation) can be selected. We accomplish this by pioneering new approaches in early detection and targeted inhibition of PAX2 and EN2 cancer oncogenes. We are also developing a cancer vaccine that utilizes Human Beta Defensin-1 (DEFB1) mRNA to selectively target cancer cells to be destroyed by the immune system.
who are we?
PHIGENIX, Inc. is a leader in Personalized Medicine and the rapidly evolving cancer diagnostic and therapeutics industry. Find out about our organization, mission, our methods, and the results of our decades of advocacy.
companion diagnostics and targeted THERAPIES
We are currently developing diagnostic tests which may detect prostate abnormalities at the pre-malignant state years before the onset of cancer. Our therapeutics in development involves blocking the expression of cancer causing proteins and the subsequent re-expression of a naturally occurring component of the immune system to fight cancer.